Literature DB >> 15605253

The 2004 Perugia Antiemetic Consensus Guideline process: methods, procedures, and participants.

Richard J Gralla1, Fausto Roila, Maurizio Tonato.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15605253     DOI： 10.1007/s00520-004-0756-5

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  2 in total

1.  Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology.

Authors:  R J Gralla; D Osoba; M G Kris; P Kirkbride; P J Hesketh; L W Chinnery; R Clark-Snow; D P Gill; S Groshen; S Grunberg; J M Koeller; G R Morrow; E A Perez; J H Silber; D G Pfister
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

Review 2.  Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC).

Authors: 
Journal:  Ann Oncol       Date:  1998-08       Impact factor: 32.976
  2 in total
  8 in total

1.  Psychosocial care for patients and their families is integral to supportive care in cancer: MASCC position statement.

Authors:  Antonella Surbone; Lea Baider; Tammy S Weitzman; Mary Jacqueline Brames; Cynthia N Rittenberg; Judith Johnson
Journal:  Support Care Cancer       Date:  2009-07-17       Impact factor: 3.603

2.  Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting.

Authors:  Henning Burmeister; Stefan Aebi; Cristina Studer; Martin F Fey; Oliver Gautschi
Journal:  Support Care Cancer       Date:  2011-01-14       Impact factor: 3.603

3.  An oral history of MASCC, its origin and development from MASCC's beginnings to 2009.

Authors:  Cynthia N Rittenberg; Judith L Johnson; Gerald M Kuncio
Journal:  Support Care Cancer       Date:  2010-03-10       Impact factor: 3.603

4.  A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design.

Authors:  P C Nathan; G Tomlinson; L L Dupuis; M L Greenberg; S Ota; U Bartels; B M Feldman
Journal:  Support Care Cancer       Date:  2005-07-29       Impact factor: 3.603

Review 5.  Oral vinorelbine: role in the management of metastatic breast cancer.

Authors:  Matti S Aapro; Pierfranco Conte; Emilio Esteban González; Véronique Trillet-Lenoir
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Less nausea, emesis, and constipation comparing hydromorphone and morphine? A prospective open-labeled investigation on cancer pain.

Authors:  S Wirz; H C Wartenberg; J Nadstawek
Journal:  Support Care Cancer       Date:  2007-12-20       Impact factor: 3.603

7.  The Role of Aprepitant in Prevention of Postoperative Nausea and Vomiting After Bariatric Surgery.

Authors:  Isaac W Therneau; Erin E Martin; Juraj Sprung; Todd A Kellogg; Darrell R Schroeder; Toby N Weingarten
Journal:  Obes Surg       Date:  2018-01       Impact factor: 4.129

8.  Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting.

Authors:  Chae Seong Lim; Young-Kwon Ko; Yoon-Hee Kim; Sang-Il Park; Jae-Kook Kim; Myoung-Joong Kim; Hyun-Joong Kim
Journal:  Korean J Anesthesiol       Date:  2013-03-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.